Pharmaron Beijing Co., Ltd. Class H ( (HK:3759) ) has shared an update.
Pharmaron Beijing Co., Ltd. has announced a board meeting scheduled for March 26, 2025, to discuss and approve the annual results for the year ended December 31, 2024, and to consider the recommendation of a final dividend payment. This meeting is significant as it will provide insights into the company’s financial performance and potential returns for shareholders, impacting its market positioning and stakeholder interests.
More about Pharmaron Beijing Co., Ltd. Class H
Pharmaron Beijing Co., Ltd. is a joint stock company incorporated in the People’s Republic of China, operating in the pharmaceutical industry. The company is involved in providing a range of services and products related to drug research and development.
YTD Price Performance: 8.77%
Average Trading Volume: 179
Technical Sentiment Consensus Rating: Sell
Current Market Cap: €5.76B
For an in-depth examination of 3759 stock, go to TipRanks’ Stock Analysis page.
Trending Articles:
Questions or Comments about the article? Write to editor@tipranks.com